Xgeva: risk of hypocalcaemia in cancer setting

Amgen has sent a letter to healthcare professionals reminding them of the risk of severe symptomatic hypocalcaemia associated with use of Xgeva (denosumab) and highlighting the potential for late-onset hypocalcaemia.

Xgeva is given by subcutaneous injection every four weeks
Xgeva is given by subcutaneous injection every four weeks

Xgeva is indicated for the prevention of skeletal events (including pathological fracture, radiation or surgery to bone, and spinal cord compression) in patients with bone metastases caused by solid tumours. Hypocalcaemia was identified as a common adverse event in clinical trials; however, severe fatal cases have been reported in the postmarketing period.

Higher risk when initiating therapy

Hypocalcaemia can occur at any time during therapy with denosumab but most commonly occurs within the first six months of dosing. In severe cases, the patient may present with altered mental status, tetany, seizures and QT interval prolongation. 

Prescribers are reminded of the following recommendations to minimise risk:

  • Correct hypocalcaemia before starting therapy
  • Administer calcium and vitamin D supplements unless hypercalcaemia is present
  • Consider additional calcium supplementation if hypocalcaemia occurs
  • Monitor calcium levels in patients with severe renal impairment (CrCl <30ml/min) or receiving dialysis.

View Xgeva drug record

View letter to healthcare professionals

Further information: Amgen

Follow MIMS on Twitter

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases